Elena López‐Knowles

10.6k citations

46 papers · 7.3k indexed · 3 hit papers · h-index 24

Molecular Biology top 1%
Oncology top 0.5%
Cancer Research top 0.5%
Genetics top 1%
Pulmonary and Respiratory Medicine top 2%

Co-authors: Mark Meuth Niklas Schultz Suzanne Kyle Helen E. Bryant Huw D. Thomas Thomas Helleday Nicola J. Curtin Mitch Dowsett
Topics: Breast Cancer Treatment Studies (17 papers)Estrogen and related hormone effects (14 papers)Advanced Breast Cancer Therapies (12 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Nature Proceedings of the National Academy of Sciences Nature Communications
Partner nations: United Kingdom United States Australia

In The Last Decade

Elena López‐Knowles

43 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

2005 3.8k citations Helen E. Bryant, Niklas Schultz et al. Nature profile →
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

2013 436 citations Mitch Dowsett, Ivana Šestak et al. profile →
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

2015 416 citations Isaac García-Murillas, Elena López‐Knowles et al. profile →

Peers

Countries citing papers authored by Elena López‐Knowles

Since Specialization

Citations

This map shows the geographic impact of Elena López‐Knowles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena López‐Knowles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena López‐Knowles more than expected).

Fields of papers citing papers by Elena López‐Knowles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena López‐Knowles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena López‐Knowles. The network helps show where Elena López‐Knowles may publish in the future.

Co-authorship network of co-authors of Elena López‐Knowles

This figure shows the co-authorship network connecting the top 25 collaborators of Elena López‐Knowles. A scholar is included among the top collaborators of Elena López‐Knowles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena López‐Knowles. Elena López‐Knowles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study 2022 ·Breast Cancer Research ·Elena López‐Knowles,Simone Detre,Margaret Hills,Eugene F. Schuster,Maggie C.U. Cheang,Holly Tovey,Lucy Kilburn,Judith M. Bliss,J.F.R. Robertson,Elizabeth Mallon,Anthony Skene,Abigail Evans,Ian Smith,Mitch Dowsett	5
2	Abstract PD15-02: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer 2022 ·Cancer Research ·(unknown),Elena López‐Knowles,(unknown),Holly Tovey,Lucy Kilburn,Chris Holcombe,Anthony Skene,Ian Smith,J.F.R. Robertson,Eugene F. Schuster,Judith M. Bliss,Mitch Dowsett,Maggie C.U. Cheang,(unknown)	0
3	Abstract PS5-01: Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial 2021 ·Cancer Research ·Eugene F. Schuster,Hui Xiao,Elena López‐Knowles,Lucy Kilburn,Mothaffar F. Rimawi,David A. Wheeler,Katherine L. Pogue–Geile,(unknown),Samuel A. Jacobs,(unknown),Shannon Puhalla,Maggie C.U. Cheang,Judith M. Bliss,Stephen Johnston,Mitch Dowsett,(unknown)	3
4	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations 2018 ·British Journal of Cancer ·Elena López‐Knowles,Alex Pearson,Eugene F. Schuster,Pascal Gellert,Ricardo Ribas,Belinda Yeo,Ros Cutts,Richard Buus,Isaac García-Murillas,Ben P. Haynes,Lesley‐Ann Martin,Ian Smith,Nicholas C. Turner,Mitch Dowsett	12
5	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas 2016 ·Breast Cancer Research ·(unknown),Elena López‐Knowles,Qiong Gao,Maggie C.U. Cheang,James P. Morden,Joel S. Parker,Lesley‐Ann Martin,(unknown),Fiona E. McNeill,Margaret Hills,Simone Detre,Maria Afentakis,Lila Zabaglo,Andrew Dodson,Anthony Skene,Chris Holcombe,J.F.R. Robertson,A. Ian Smith,Judith M. Bliss,Mitch Dowsett	20
6	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype 2015 ·Annals of Oncology ·Michael Gnant,Ivana Šestak,Martin Filipits,Mitch Dowsett,Marija Balić,Elena López‐Knowles,Richard Greil,Peter Dubsky,Herbert Stoeger,Margaretha Rudas,R. Jakesz,Sean Ferree,J. Wayne Cowens,Torsten O. Nielsen,Carl Schaper,Christian Fesl,Jack Cuzick	77
7	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer 2015 ·Breast Cancer Research ·Elena López‐Knowles,Paul M Wilkerson,Ricardo Ribas,H Anderson,Alan Mackay,Zara Ghazoui,Aradhana Rani,Peter Osin,A Nerurkar,Lorna Renshaw,Alexey A. Larionov,William R. Miller,J. Michael Dixon,Jorge S. Reis‐Filho,Anita K. Dunbier,Lesley‐Ann Martin,Mitch Dowsett	7
8	Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer 2013 ·JNCI Journal of the National Cancer Institute ·Ivana Šestak,Mitch Dowsett,Lila Zabaglo,Elena López‐Knowles,Sean Ferree,J. Wayne Cowens,Jack Cuzick	170
9	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population 2013 ·The Lancet Oncology ·Dennis C. Sgroi,Ivana Šestak,Jack Cuzick,Yi Zhang,Catherine A. Schnabel,Brock E. Schroeder,Mark G. Erlander,Anita K. Dunbier,Kally Sidhu,Elena López‐Knowles,Paul E. Goss,Mitch Dowsett	275
10	Relationship of PIK3CA Mutation and PI3K Pathway Activity with Antiproliferative Response to Anastrozole in Er+ Breast Cancer 2013 ·Annals of Oncology ·(unknown),Elena López‐Knowles,(unknown),Isaac García-Murillas,Nicholas C. Turner,Lesley‐Ann Martin,Mitch Dowsett	1
11	ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1 2011 ·PLoS Genetics ·Anita K. Dunbier,H Anderson,Zara Ghazoui,Elena López‐Knowles,Sunil Pancholi,Ricardo Ribas,Suzanne Drury,Kally Sidhu,Alexandra Léary,Lesley‐Ann Martin,Mitch Dowsett	43
12	S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study. 2011 ·Cancer Research ·Mitch Dowsett,Elena López‐Knowles,Kiran Sidhu,Sílvia Pineda,(unknown),Sean Ferree,James J. Storhoff,Carl Schaper,Jack Cuzick	8
13	High Notch1 protein expression is an early event in breast cancer development and is associated with the HER‐2 molecular subtype 2010 ·Histopathology ·(unknown),Ibrahim M. Zardawi,Catriona M. McNeil,Ewan K.A. Millar,Duncan McLeod,Adrienne Morey,Paul Crea,Niamh Murphy,Mark Pinese,Elena López‐Knowles,Samantha R. Oakes,Christopher J. Ormandy,Min Qiu,Anne Hamilton,Andrew J. Spillane,Cheok Soon Lee,Robert L. Sutherland,Elizabeth A. Musgrove,Sandra O’Toole	48
14	PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality 2009 ·International Journal of Cancer ·Elena López‐Knowles,Sandra O’Toole,Catriona M. McNeil,Ewan K.A. Millar,Min Qiu,Paul Crea,Roger J. Daly,Elizabeth A. Musgrove,Robert L. Sutherland	247
15	PI3K Pathway Activation in Breast Cancer Is Associated with the Basal-Like Phenotype and Cancer-Specific Mortality. 2009 ·Cancer Research ·Elena López‐Knowles,Sandra A. O’Toole,Sandra O’Toole,Catriona M. McNeil,Ewan K.A. Millar,Min Qiu,Min Qiu,Paul Crea,(unknown),(unknown),Elizabeth A. Musgrove,R. Sutherland,R. L. Sutherland	13
16	Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern 2007 ·Proceedings of the National Academy of Sciences ·Christian Hafner,Elena López‐Knowles,Nuno Miguel Luis,Agustí Toll,Eulàlia Baselga,(unknown),Sílvia Hernández,Adriana Ribé,Thomas Mentzel,Robert Stoehr,Ferdinand Hofstaedter,Michael Landthaler,Thomas Vogt,Ramón M. Pujol,Arndt Hartmann,Francisco X. Real	138
17	Molecular biology of bladder cancer 2007 ·Clinical & Translational Oncology ·Nuno Miguel Luis,Elena López‐Knowles,Francisco X. Real	26
18	The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors 2006 ·Clinical Cancer Research ·Elena López‐Knowles,Sílvia Hernández,Manolis Kogevinas,Josep Lloreta,(unknown),Adonina Tardón,Alfredo Carrato,Sirish Kishore,Cònsol Serra,Núria Malats,Francisco X. Real,(unknown)	45
19	PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors 2006 ·Cancer Research ·Elena López‐Knowles,Sílvia Hernández,Núria Malats,Manolis Kogevinas,Josep Lloreta,Alfredo Carrato,Adonina Tardón,Cònsol Serra,Francisco X. Real,(unknown)	155
20	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerasebreakdown → 2005 ·Nature ·Helen E. Bryant,Niklas Schultz,Huw D. Thomas,(unknown),(unknown),Elena López‐Knowles,Suzanne Kyle,Mark Meuth,Nicola J. Curtin,Thomas Helleday	3780

About Elena López‐Knowles

Elena López‐Knowles is a scholar working on Cancer Research, Oncology and Genetics, having authored 46 papers that have together received 7.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (17 papers), Estrogen and related hormone effects (14 papers) and Advanced Breast Cancer Therapies (12 papers). The work is most often cited by research in Oncology (4.3k citations), Cancer Research (2.1k citations) and Molecular Biology (4.6k citations). Elena López‐Knowles has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Mark Meuth, Niklas Schultz, Suzanne Kyle, Helen E. Bryant, Huw D. Thomas, Thomas Helleday, Nicola J. Curtin, Mitch Dowsett, Jack Cuzick and Ivana Šestak. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact